We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Defeat Leaves Molecular Scar in Brain

By Biotechdaily staff writers
Posted on 15 Mar 2006
Researchers studying a mouse model of depression found that repeated defeat by dominant animals leaves a mouse with an enduring molecular scar in its brain, which may help to explain why depression is so difficult to cure.

In the mouse model, silencer molecules turned off a gene for a key protein in the brain's hippocampus. More...
After activating a compensatory mechanism, an antidepressant was able to temporarily restore the animal's sociability and the protein's expression but failed to remove the silencers. A true cure for depression would probably have to target this scar, according to the researchers, from the University of Texas Southwestern Medical Center (Dallas, TX, USA). Their findings were reported in the February 26, 2006, online edition of Nature Neuroscience.

Mice exposed to aggression by a different dominant mouse daily for 10 days became socially defeated and strongly avoided other mice, even weeks later. The expression of a representative gene in the hippocampus, a memory center implicated in depression, fell three-fold and remained suppressed for weeks. Chronic treatment with imipramine, a tricyclic antidepressant, restored expression of the gene for brain-derived neurotrophic factor (BDNF) to normal levels and reversed social withdrawal behavior.

The researchers traced the gene expression changes to long-lasting modifications in histones, which are proteins that regulate the turning on-and-off of genes via methylation. The drug imipramine was unable to remove these silencer molecules, suggesting that they remained as a latent source of vulnerability to future stress.

"The molecular scar induced by chronic stress in the hippocampus, and perhaps elsewhere in the brain, can't easily be reversed,” noted lead researcher Eric Nestler, M.D., of the Southwestern Medical Center. "To really cure depression, we probably need to find new treatments that can remove the silencer molecules.”



Related Links:
U. Texas Southwestern Medical Center

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.